Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lupus drug candidate enters first human tests

NCT ID NCT05411016

Ongoing Disease control Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. It is too early to know if it works, but results will guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KK4277
What this could lead to
If safe, this could pave the way for larger studies testing whether KK4277 helps control lupus symptoms.
What could go wrong
This is a very early Phase 1 trial focused only on safety and dosing. It is too small and early to know if KK4277 works for lupus, and many early-stage drugs fail.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) HEALTHY VOLUNTEERS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, Gyeonggi-do, 16499, South Korea

  • Fujita Health University Hospital

    Kutsukake, Aichi-ken, 470-1192, Japan

  • Fukushima Medical University Hospital

    Fukushima, 960-1295, Japan

  • Institute of Science Tokyo Hospital

    Bunkyō-Ku, Tokyo, 113-8519, Japan

  • Japan Community Health care Organization Chukyo Hospital

    Minami, Aichi-ken, 457-8510, Japan

  • Japan Institute for Health Security National Center for Global Health and Medicine

    Shinjuku-Ku, Tokyo, 162-8655, Japan

  • Juntendo University Nerima Hospital

    Tokyo, 177-8521, Japan

  • Juntendo University Urayasu Hospital

    Urayasu, Chiba, 279-0021, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • Keio University Hospital

    Shinjuku-Ku, Tokyo, 160-8582, Japan

  • Kitasato University Hospital

    Minami, Kanagawa, 252-0375, Japan

  • Kyusyu University Hospital

    Higashi, Fukuoka, 812-8582, Japan

  • Medical Co. LTA Sumida Hospital

    Sumida-ku, Tokyo, 130-0004, Japan

  • Nagasaki University Hospital

    Nagasaki, 852-8501, Japan

  • National University Corporation Tohoku University Tohoku University Hospital

    Aoba, Miyagi, 980-8574, Japan

  • Niigata University Medical & Dental Hospital

    Chuo Ku, Niigata, 951-8520, Japan

  • Saitama Medical University Hospital

    Moriyama, Saitama, 350-0495, Japan

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Showa Medical University East Hospital

    Shinagawa-Ku, Tokyo, 142-0054, Japan

  • St. Luke's International Hospital

    Chuo Ku, Tokyo, 104-8560, Japan

  • University of the Ryukyus Hospital

    Ginowan, Okinawa, 901-2725, Japan

  • Wakayama Medical University Hospital

    Wakayama, 641-8510, Japan

  • Yokohama City University Medical Center

    Minami, Kanagawa, 232-0024, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.